Abstract:Abstract Recent evidence suggested that cancer patient-derived explant mouse models can maintain certain pathological and molecular features of the original diseases/patients, which offers potential opportunities for testing “personalized medicine” preclinically. We have established over 20 HCC explant models by directly implanting fresh tumor tissues derived from HCC patients into immunodeficient mice. To assess whether these HCC models would represent HCC clinical characteristics and individual patient diversity, we have compared the molecular profiles of these xenografts with their corresponding patient tissues (F0). This included gene copy variation by aCGH, mRNA expression by Affymetrix and gene mutations as well as protein expressions by immunohistochemistry. In addition, we also assessed the stability of the molecular profiles of various models by comparing different passages (F1-F10). Analysis of the data revealed that the xenograft tumors maintain fundamental genotypic features of the original patients, which recapitulate the genetic diversity of the HCC. The assessment on the stability of molecular profiles of individual model based on Pearson correlation coefficient (r) of aCGH data from different passages (F1-F10) suggests that those HCC models are very stable across passages (r > 0.8). In addition, no dramatic changes of the known molecular and histological features were observed throughout serial passages. AFP mRNA expressions of various models by Affymetrix are very different and mirror patient clinical data very well. Amplification of myc and cycline D1 and deletion of DLC1 and FHIT were detected in different individual models, as well as in corresponding patient HCC tissues, and those aberrations are consistent throughout the passages within various individual model. Furthermore, passages of the tumors in successive cohorts of mice did not change their sensitivity to sorafenib. In summary, we have developed preclinical HCC patient-derived explant models that can be used to further understand the disease and develop mechanism-based anti-cancer drugs for treatment of HCC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2412. doi:10.1158/1538-7445.AM2011-2412

Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine

Patient-derived 3D Bioprinting Pan-Cancer Drug Screening Platform for Personalized Medicine.

Metastasis-on-a-chip Mimicking the Progression of Kidney Cancer in the Liver for Predicting Treatment Efficacy

Application of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research.

Bioprinting of patient-derived in vitro intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing.

Bioprinting of patient-derived<i>in vitro</i>intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing

A Three-Dimensional Cell Biology Model of Human Hepatocellular Carcinoma in Vitro

Bioprinting of a Hepatic Tissue Model Using Human-Induced Pluripotent Stem Cell-derived Hepatocytes for Drug-Induced Hepatotoxicity Evaluation.

Developing Patient-Derived 3D-Bioprinting models of pancreatic cancer

Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient‐Derived Xenograft Assays

Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models

Spheroid On-Demand Printing and Drug Screening of Endothelialized Hepatocellular Carcinoma Model at Different Stages.

3D bioprinting of an in vitro hepatoma microenvironment model: Establishment, evaluation, and anticancer drug testing

Bioprinting of Novel 3D Tumor Array Chip for Drug Screening

Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure

Three-dimensional printing: review of application in medicine and hepatic surgery

3D printing of self-healing personalized liver models for surgical training and preoperative planning

Application of 3D Bioprinting in Liver Diseases

Prediction of Clinical Precision Chemotherapy by Patient‐Derived 3D Bioprinting Models of Colorectal Cancer and Its Liver Metastases

Abstract 2412: Molecular Characterization of Hepatocellular Carcinoma (HCC) Patient-Derived Explant Models

Advancements and application prospects of three-dimensional models for primary liver cancer: a comprehensive review